Dr. William J. (Bill) Welsh holds the Norman H. Edelman Professorship in Bioinformatics in the Department of Pharmacology at the Robert Wood Johnson Medical School (RWJMS), Rutgers University in Piscataway NJ. Concurrently, he serves as Associate Director of Cheminformatics at the Rutgers-Cancer Institute of New Jersey.  Dr. Welsh’s laboratory specializes in the development and application of computational tools for molecular discovery, predictive toxicology,  and rational design of small molecule drugs and polymeric materials. His publication record includes over 400 articles in peer-reviewed books and journals, 200 abstracts for presentations at professional scientific meetings, and numerous patents and patent applications. He is the recipient of several awards and honors, including the St. Louis Research Award (1998), the University of Missouri-St. Louis Chancellor’s Research and Creativity Award (2001), and the University of Missouri Entrepreneur of the Year Award (2001). Spanning the last twenty-five years, over 350 students have trained in his laboratory. Dr. Welsh earned a BS degree in Chemistry from St. Joseph’s University (Philadelphia, PA) and a PhD in Theoretical Physical Chemistry from the University of Pennsylvania (Philadelphia, PA). He completed postdoctoral studies at the University of Cincinnati Department of Chemistry in the laboratory of Dr. James E. Mark, and held sabbatical appointments at the National Institutes of Health-National Library of Medicine (1984-85) and at Princeton University Department of Chemistry in the laboratory of Dr. Herschel Rabitz (2012-13). He founded Snowdon in 2007.

Board of Directors

James M. Golubieski is president of Foundation Venture Capital Group and New Jersey Health Foundation. Mr. Golubieski had been chief financial officer of Array Medical, Inc., a medical device company established in 1995 that developed a groundbreaking blood test to assess platelet function. The company was sold in 1999. Previously, he was chief operating officer and senior executive vice president of Glendale National Bank and a member of its board of directors, president of Glendale Investment Corporation and Glendale Mortgage Services, Inc. and chief financial officer of Glendale Bancorp. For 10 years prior, he had been with KPMG, one of the largest professional services companies in the world. Mr. Golubieski is a member of the New Jersey Economic Development Authority’s Technology Advisory Board, which evaluates and recommends start-up companies for investment and the New Jersey Department of Labor and Workforce Development’s BIO-1 Project, a plan to retain and expand high-quality jobs in central New Jersey’s bioscience sector.

George F. Heinrich, MD, is the vice chair and chief executive officer of Foundation Venture Capital Group, a position he also holds with New Jersey Health Foundation. Dr. Heinrich received his MD degree from New Jersey Medical School and served his residency in Internal Medicine at Martland Hospital in Newark. He has dedicated his career to the advancement of medical research and education and has served in a variety of capacities on many boards including those of hospitals, medical centers, nursing homes and charitable organizations within New Jersey and New York.


Vincent A. Smeraglia, Esq. is the Executive Director, Strategic Alliances, developing Rutgers collaborative relationships with universities, foundations, and corporate partners.  Previously, Mr. Smeraglia was the Executive Director of the Rutgers office of Technology Commercialization overseeing patenting and licensing of Rutgers inventions.  Mr. Smeraglia was also the Executive Director of the UMDNJ Office of Technology Transfer & Business Development.  He has also conducted biomedical research at Cytogen Corporation, developing antibody conjugates for diagnostic and therapeutic clinical uses.  Mr. Smeraglia has a B.S. in Biochemistry from Rutgers and a Masters of Intellectual Property and J.D. from the University of New Hampshire Law School.